Deutsche Märkte geschlossen

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
12,24+0,08 (+0,66%)
Börsenschluss: 04:00PM EDT
12,32 +0,08 (+0,65%)
Nachbörse: 07:23PM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter264

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. James C. MullenExec. Chairman1,01MN/A1959
Ms. Michelle RobertsonCFO, Principal Accounting Officer, Treasurer & Assistant Sec.641,74k101,88k1967
Dr. Mark S. ShearmanExec. VP & Chief Scientific Officer639,89kN/A1960
Dr. Bruce E. Eaton Ph.D.Exec. VP & Chief Bus. Officer1,09MN/A1954
Dr. Gilmore O'NeillPres & CEON/AN/A1964
Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/A1954
Dr. J. Keith Joung M.D., Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Mr. Harry R. Gill IIISr. VP of OperationsN/AN/A1961
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.s ISS Governance QualityScore, Stand 28. September 2022, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.